<DOC>
	<DOCNO>NCT00001940</DOCNO>
	<brief_summary>Voriconazole new drug develop treat fungal infection . As March 1999 , drug study 1,900 healthy volunteer patient fungal infection . This study test extend use voriconazole patient serious fungal infection approve therapy , patient improve could tolerate standard therapy . It evaluate drug 's safety , effectiveness , toleration patient . Patients previous enrol protocol 99-C-0094 improved voriconazole treatment eligible study . Before begin treatment , patient physical examination , include blood urine test , eye examination . They may also X-ray CT image . Voriconazole give twice day either infusion vein tablets take mouth 12 week . Patients examine week 4 , 8 12 study one week treatment stop . Blood urine sample collect visit . An eye examination do end treatment period visit vision problem develop . Voriconazole active fungal infection may produce few side effect standard therapy .</brief_summary>
	<brief_title>Voriconazole Treat Fungal Infections</brief_title>
	<detailed_description>The objective study evaluate efficacy , safety toleration voriconazole treatment systemic invasive fungal infection due fungal pathogen license therapy unresponsive intolerant treatment approve systemic antifungal agent . This trial extension Phase III multicenter , open label study investigate utilization voriconazole treatment systemic invasive fungal infection . Enrollment target 100 patient recruited multiple center . The patient population consist patient proven deeply invasive fungal infection license therapy patient fail intolerant treatment approve systemic antifungal agent currently voriconazole ( 99-C-0094 ) protocol . Voriconazole administer intravenously 3-4 mg/kg q 12 hour orally 200-300 mg BID . Efficacy evaluate clinical , radiological microbiological response .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Males ( nonpregnant , lactate nursing ) females equal great 12 year age . Previous enrollment completion voriconazole therapy protocol 99C0094 investigating use voriconazole treatment invasive fungal disease empirical treatment presume fungal infection enrol within three week completion 99C0094B . Clinical benefit derive previous voriconazole treatment . Further clinical benefit expect extended voriconazole treatment . Women child bear potential ( less 2 year post menopausal ) must negative serum pregnancy test baseline , must agree use barrier method contraception study . Signed write informed consent must obtain protocol entry . Assent obtain minor capable understanding . Subjects must either ongoing serious adverse event probably related voriconazole therapy ongoing adverse event probably related voriconazole therapy may pose significant risk continue therapy . Must previously participate trial . If receiving , must able discontinue follow drug least 24 hour prior randomization : terfenadine , cisapride , astemizole . If receiving , must able discontinue sulphonylureas least 24 hour prior randomization . Must receive follow drug within 14 day prior randomization : rifampin , carbamazepine , barbiturate . Must AST , ALT , great 10 ( upper limit normal ) . Must serum creatinine great 3.0 mg/dl .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2000</verification_date>
	<keyword>Antifungal Agent</keyword>
	<keyword>Aspergillosis</keyword>
	<keyword>Candidemia</keyword>
	<keyword>Fungemia</keyword>
</DOC>